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Summary
The plasma levels of coagulation factor VII and fibrmogen aie well
known nsk factors for artenal thrombosis We tested the hypothesis
that this assoctaüon also exists for venous thrombosis Additionally,
Mspl and Haelü polymoφhlsms m the factor VII and fibrmogen genes
have recently been reported to be associated with the concentration of
both protems m the plasma However, no conclusion could be drawn
with respect to an increase or decrease m thrombosis nsk We under-
took a population-based case control study, m which 199 patients with
a first, objecüvely confirmed episode of deep vem thrombosis, aged
less than 70, and without a known mahgnant disorder were compared
to 199 age- and sex-matched healthy controls, to evaluate the clmical
impoitance of these reported fmdmgs
For fibrmogen we found a positive level-ielated association between
the plasma fibrmogen level and thrombotic nsk Subjects with a
plasma fibrmogen greater than 5 g/l had an almost 4 fold increase of
thrombosis nsk The frequencies of the different Haelll genotypes
were out of balance only for the thiombosis patients, with a deficit of
the H1H2 genotype Possession of an H1H2 genotype was associated
with a 40% reduction m thrombosis risk
For factor VII, neithei the plasma level nor the Mspl genotypes
were related to deep vem thrombosis, although possession of a M2
allele was clearly associated with sigmficantly lower factor VII levels
The frequencies of the Mspl-genotypes weie the same for patients and
control subjects and exhibited Hardy-Weinberg equilibnum
Our results support that plasma fibrmogen, a determmant of aitenal
thrombosis is also a risk factor for venous thrombosis, while factor VII
plasma concentration is unrelated to deep vem thrombosis, which is
supported by the data from the DNA analysis of polymorphisms
Introduction
Deep vem thrombosis is a common disordei (1) The numerous
causes of thrombosis mclude both hereditary and acquired conditions
(2) However, despite our knowledge of these risk factors, most epi-
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sodes of deep vem thrombosis seem to occui spontaneously This
suggests that theie are additional mechamsms for the development of
venous thrombosis, yet to be discovered We investigated two key com-
ponents of the extnnsic and common clottmg pathway, factor VII and
fibrmogen Patients deficient foi factor VII or fibrmogen suffer from a
tendency to bleed (3,4, 5) On the othei hand, higher mean factor VII
levels were found in 25 patients with deep-vem thrombosis than m 38
control subjects, suggestmg that there might be an association (6)
Elevated plasma levels of both factor VII and fibrmogen aie well
estabhshed nsk factois for artenal thiombosis (7-9) We tested the
hypothesis that these associations also exist for venous thrombosis
Many envuonmental factois mfluence the plasma levels of both fac-
toi VII and fibrmogen (10-12) They do not explam all the vanations
among individuals, and genes contnbute äs well (13) Several reports
have been pubhshed which showed a clear relation between plasma
levels and genetic factors exammed through restlichen fragment length
polymorphism (RFLP) techniques (14-17) Since these studies were
hmited to healthy individuals, they offered no Information on a lelation
between a ceitam genotype or plasma levels and the nsk of thrombosis
In the present study, we have investigated the clmical importance of
the association between plasma levels and RFLPs m 199 unselected
consecutive patients, aged less than 70, with a first, objectively con-
firmed episode of deep vem thrombosis and without a known mahgnant
disease We compared the plasma concentrations of factor VII and
fibrmogen and the allele frequencies of the RFLPs m patients and age-
and sex matched healthy control subjects This work was performed äs
pait of an ongomg population-based case-control study on hereditaiy
venous thrombosis called the Leiden Thrombophilia Study (LETS)
Materials and Methods
Selectwn of Patients and Control Subjects
Patients were selected fiom the Computer flies of the Anticoagulation Clmic
m Leiden In the Netherlands, Anticoagulation Clmics momtor coumarm
treatment m virtually all patients with venous thrombosis and this treatment is
invanably monitored by a legional Anticoagulation Clmic (18,19) Each Anti
coagulation Clmic serves a well defmed geographical area, which for the
Leiden Anticoagulation Clmic has about 450,000 mhabitants We mcluded the
first 220 consecutive out-patients of this well defmed geographical area, youn-
gei than 70 yeais, who were lefened foi anticoagulant treatment after a first,
objectively diagnosed, episode of deep vem thrombosis that occurred between
January l, 1988 and December 31, 1992 Patients with known mahgnant dis
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Orders were excluded Information about the mclusion and exclusion cntena
was obtamed from general practitioners and discharge records from the hospi
tals Patients were seen only after anticoagulant treatment had been discon-
tinued for at least thiee months The median Urne between the occurrence of
deep vein thrombosis and venepuncture for this study was 15 (ränge 6-44)
months The response of the ehgible patients was high (91 percent)
Each thiombosis patient was asked to find his own healthy control subject
accordmg to the followmg cntena same sex, about the same age (± five years),
no biologic relative and no history of venous thiomboembohsm no use of
coumanns for at least three months not known with a mahgnant disorder and
mhabitant of the same geographical area Partners of patients were also mvited
to serve äs control subjects When a patient was unable to find a control subject,
the first mdividual from this hst of partneis who matched for age and sex was
asked to jom the study 91 (46%) control subjects were partners of other pa-
tients
crease or decrease m factor VII01 fibnnogen plasma levels per umt mcrease m
the factor studied, adjusted for the effect of other variables in the model and the
matchmg factors age and sex
Smce plasma factoi VII and fibnnogen levels are contmuous variables we
calculated matched odds ratios, äs estimates of the relative nsk, over several
strata of exposure, with 95% confidence limits The odds ratio reflects the
thrombosis nsk when a factor is present relative to the nsk when it is absent, ad-
justed for the matchmg factors When the 95% confidence interval of the odds
ratio does not mclude unity, the odds ratio is different from umty at a signifi
cance level of 5% or less As possible confounders we mcluded smokmg, alco-
hol mtake oral contraceptive use, menopausal Status, pregnancy and body mass
mdex Adjustment for these possible confounders was accomplished by
entenng all mto a (conditional) logistic regression model (Egret® Software)
(21) Smce genes cannotbe mfluenced by any of these confoundeis, only crude
odds ratios are provided for the Mspl and Haelll RFLPs
Collection of the Data
All subjects completed a Standard questionnaire, which contamed questions
about variables which are known or suspected to mfluence factor VII or
fibrmogen levels smokmg, alcohol mtake, oral contraceptive use, menopausal
state pregnancy history of artenal thrombosis (11, 20) Blood pressure and
body mass mdex (weight/height squared) were measured under Standard condi
üons for every participant at the study center Blood was collected from the
antecubital vem m Saistedt Monovette0 tubes, contammg 0 106 mM tnsodium
citrate Plasma was prepared by centnfugation for 10 mm at 2000 X g at loom
temperature and stored at -70° C High moleculai weight DNA was isolated
from leucocytes and stored at -4° C Factor VII was measured usmg Thrombo
rel° S reagent (Behnngwerke AG, Warburg, Germany) and Factor VII defi
cient plasma (Organen Tekmca, Durham, USA) The fibnnogen concentration
was determmed accordmg to method of Clauss usmg Dade° thrombin reagent
(Baxter, Miami, USA) Both tests were performed on an Electra 1000 (MLA
Pleasantville, USA) For the factor VII and fibrmogen gene we used Mspl and
Haelll restnction enzymes äs reported by Green and Thomas, respectively
(15-16) The alleles with the restnction site were designated Ml (VII) and Hl
(fibrmogen) and the non cleaveable alleles were designated M2 (VII) and H2
(fibrmogen)
Analysis and Statistics
Twenty-one patients were on long term coumarm treatment and were ex-
cluded from this analysis, which therefore mcluded 199 matched patient-con-
trol pairs A chi-square test was used to compare the observed numbers of each
genotype with those expected for a population m Hardy-Wemberg equilibnum
We analyzed the effect of the polymorphic genotype on plasma factor VII
and fibrmogen levels for patients and control subjects by multivanate linear
regression techmques Factor VII and fibrmogen levels were entered äs conti-
nuous variables The Mspl and Haelll genotype and the Status of an mdividual
(patient or control subject) were entered äs discrete variables (0 for 1-1, l for
1-2 and 2 for 2-2 genotype, and 0 for control subjects l for patients, respec-
tively) The regression coefficient obtamed by this method indicates the m-
Results
The male/female ratio among patients and control subjects was l/l 5
and mean age was 44 years (ränge 17-70 patients, 17-71 controls) The
mean body mass mdex was slightly higher m patients than in the con-
trol subjects (26 3 versus 25 3 kg/m2) Table l shows mean factor VII
and fibrmogen levels for other charactenstics of the patients and control
subjects Oral contraceptive use and post-menopausal states were more
frequent among the control subjects and tended to be related to higher
levels of factor VII and fibnnogen compared to non-users and pre
menopausal states, respectively
Table 2 gives the results on factor VII and fibnnogen plasma levels
and thrombosis nsk The odds ratios for the plasma factor VII strata dtd
not differ from umty, but the nsk of venous thrombosis was related to
the fibnnogen level Subjects with a fibnnogen level between 4 and
5 g/l had a twofold higher nsk than those m the refeience category
(<3 0 g/l) Beyond 5 g/l of fibrmogen an even stionger association was
present, but äs a consequence of a low number of subjects the confi-
dence interval remamed wide The association persisted when control-
1mg for the possible confounders The uncategonzed odds ratios, which
apply over the whole ränge, were l 02 (95% confidence interval
0 99-1 03) for (each percent change in) factor VII, and l 4 (95% con-
fidence interval l 02-1 95) for (each gram/l change in) fibrmogen
Whether or not a certain genotype is associated with thrombosis, the
allele distnbution of control subjects should be m Hardy Weinberg equi-
hbnum, smce they are selected from the general population The pa-
tients, however, were mcluded because of their episode of deep vem
thrombosis If a relation exists between deep vem thrombosis and a cer-
tain genotype, the allele frequencies will be out of balance, with over-
representation of the nsk enhancmg allele In Table 3 the frequencies of
the different alleles are presented As expected, the control group was
m equilibnum for the Mspl and Haelll polymorphisms In the throm-
Table l Mean factor VII and fibrmogen levels for several charactenstics of the patients and control subjectsf
Smokers
Females usmg oral contraceptives
yes
no
Females m menopause
yes
no
Factor VII (%)
patients
111(37%)
114(15%)
110(85%)
116(18%)
108 (82 %)
controls
109(36%)
121 (24 %)
108(76%)
120 (24 %)
107 (76 %)
Fibrmogen (g/l)
patients controls
34
35
33
37
33
33
32
32
34
32
* At the time of the venepuncture while visitmg the study center
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Table 2 Thrombosis nsk for factor VII and fibrinogen plasma levels Table 4 Thrombosis nsk for the differenl Mspl and Haelll genotypes
Risk factoi
Factor VII (%)
Fibrinogen (g/l)
<85
85-109
>110
<30
30-39
40^19
>50
Gases
27
78
94
64
105
24
6
Contiols
23
79
97
78
105
14
2
ORcmdc(95%CI)'
10 2 3
08(04-16)
0 8 (0 4-1 5)
1 0 9 3 4
1 3 (0 8-2 0)
2 1 (1 (M 5)
37(07-19)
OR denotes age and sex-matched odds raüo 2Reference category 3Adjust
ment for current pill use (yes/no), body mass mdex, in menopause (yes/no),
alcohol use (non/low/high) and smoking (yes/no) did not affect these results
None of the female participants were pregnant at the time of the venepuncture
"Test for trend p <0 05
Table 3 Frequencies of the Mspl and Haelll genotypes m patients and
controls
Genotype m RFLP
Patients 1-1
1-2
2-2
Controls 1-1
1-2
2-2
Mspl polytnorphism
observed expected1
164 1646
34 328
1 16
X2 = 027 (ns)2
162 161
34 36
3 2
A2 = 0 59 (m)2
Haelll polymorphism
observed expected1
144 1377
43 557
12 56
X' = 105(p<001)
127 1254
62 651
10 85
X2 = 0 43 (ns)2
'For a population m Hardy Weinberg equihbnum with /; A alleles and q a
alleles the expected genotype distibutation was assessed usmg the equation
p2 AA + 2pq Aa + q2 aa = l
2ns denotes not sigmficant at the 5 % level
FVII activity (%) fibrinogen (g/j)
130
120-
110-
100-
90-
80
-38
-36
-34
-32
26
1-1 1-2 2-2
Polymorphic genotype
Fig l Mean factor VII activity and fibrinogen plasma level by polymorphic
genotype and mdividual Status (patient or control) in 199 thrombosis patients
and 199 age and sex matched healthy controls ·—· denotes factor VII
levels m thrombosis patients ·—· denotes factor VII levels in healthy
controls A—A denotes fibrinogen levels m thrombosis patients A—A
denotes fibrinogen levels m healthy controls The ränge of each Y-axis reflects
approximately the mean ± l Standard deviation for the group äs a whole
(199 patients and 199 controls)
Risk factor
Factoi VII Mspl RFLP
Fibrinogen Haelll RFLP
OddsRatiomalched 95%CI
1-1
1-2
2-2
1-1
1-2
2-2
101
10
03
101
06
1 1
06-17
0 03-3 2
04-10
05-25
'Referencecategory
bosis patients, the observed frequencies of factor VIIMl andM2 alleles
were m equihbnum In addition, the frequency of the Mspl genotypes
was the same for patients and control subjects, supporting that they
ongmated from the same source population The observed frequencies
of fibrinogen Hl and H2 alleles were sigmficantly different from the
expected ones, with less counts of the H1H2 genotype in the patients
Figure l shows the mean levels of factor VII activity and fibrinogen
for each genotype for patients and contiol subjects For factor VII a
clear association was present between the Mspl genotype and the plas-
ma levels of factor VII, the M2 allele being associated with lower levels
(legression coefficient -13 9, 95% CI -19 3 to -8 6) We found no
obvious relation between genotype and plasma fibrinogen level (re-
gression coefficient 0 04,95% CI -0 07 to 0 15), without any subgroup
effect for smokeis (data not shown) Even when only Haelll 1-2 and
2-2 genotypes were considered, no sigmficant association could be
observed
Table 4 gives the thrombosis nsk for the several polymorphic geno-
types Foi the factoi VII Mspl genotypes we did not find any relation
with deep vem thiombosis, although the Mspl genotypes correlated
well with the plasma levels For the fibrinogen Haelll genotypes we
found that subjects with one H2 allele, had a sigmficant 40% reduction
m the nsk of venous thrombosis compared to HIHI mdividuals
Discussion
Among 199 patients, younger than 70 years of age, with a first ob-
jectively confirmed episode of venous thrombosis and without a known
mahgnant disorder, and 199 age- and sex-matched healthy control sub-
jects, we found an association between the Mspl genotype and factor
VII levels, but neither Mspl genotypes nor factor VII levels were relat-
ed to an mcrease or decrease in thrombosis nsk For fibrinogen it seems
the öfter way round, we found a clear association between nsk of
thrombosis and fibrinogen levels, which nsk mcreased with higher
levels of fibrinogen Subjects with H1H2 genotype seemed to have a
40% reduction m the nsk of thrombosis, but no association was present
between plasma fibrinogen and polymorphic genotype
The fmding of a positive trend between fibrinogen levels and the
enhanced nsk of developmg venous thrombosis seems analogous to the
role of fibrinogen at the artenal site An explanation might be that
elevation of the fibrinogen level increases blood viscosity, which may
further enhance the nsk of thrombus formation (22) Furthermore, m-
creasing levels of fibrinogen withm the physiological ränge mfluences
platelet aggregation m vitro (23) In our study design we cannot discn-
mmate whether a high fibrinogen level is a nsk factor per se or a post-
thrombotic phenomenon or the result of another, true nsk factor The
venepuncture for this study was performed at least six months (on aver-
age 18 months) after the acute thrombotic event Therefore, a post-hoc
phenomenon seems less likely an explanation
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In sequence to an mcreasmg number of reports about certam restnc-
tion length polymorphisms and plasma levels of factor VII and fibrmo-
gen, we were able to link our RFLP-data to the nsk of venous throm-
botic disease We found that VII levels or Mspl genotype are not
related to venous thrombosis, but we could confirm the results of
Green et al (15) that possession of a M2 allele is associated with
lower factor VII levels In contrast to the fmdmgs of others (16,24), we
found no relation between fibnnogen levels and the Haelll genotypes,
though subjects who are homozygous for the H2 allele had higher
levels Possibly because of a low number of H2H2-subjects this could
not reach statistical sigmficance The unclear association between
Healll genotype and fibnnogen levels (mteraction with srnokmg) m yet
another study m myocardial infarction survivors (25), makes one
wonder about possible differences between populations We did not
find any subgroup effect for smokers
We cannot easily explam why Haelll 1-2 mdividuals seemed to
have a 40% reduction m the nsk of venous thrombosis, especially when
it is assumed that H2-mdividuals have higher fibnnogen levels Inter-
estingly, a similar effect, albeit not significant, was recently reported
for myocaidial mfarcüon, i e a 10-20% reduction of risk for those who
carned an H2 allele (24) Therefore, we do not thmk this was a chance
occurrence
Our control group was m perfect Hardy-Weinberg equilibnum for
the Mspl and Haelll alleles This was to be expected since the control
subjects were chosen from the general population The patient group
showed a disequilibnum for the Haelll alleles Smce we selected these
patients from the same geographical area and solely on the basis of their
deep vem thrombosis, it is plausible that we selected on a certam geno-
type which is associated with venous thrombosis This finding is of m-
terest since it also pomts to an effect of fibnnogen on the risk of venous
thrombosis which cannot be explamed by the plasma level
In addition, another mterestmg pomt raised by the Hardy-Weinberg
equilibnum seems the possibihty to check the genetic comparabihty of
patients and control subjects by usmg a parameter which is irrelevant
for the disease of mterest For mstance, since factor VII plasma levels
and polymorphic Mspl genotypes are unrelated to deep vem thrombo-
sis, one will expect both patients and control subjects to exhibit equili-
bnum, and also that the frequencies of each genotype are equal for pa-
tients and control subjects Disequihbnum among cases suggests an as-
sociation with disease, whereas equilibnum in cases and control sub-
jects, but different allele frequencies suggests mcomparability of cases
and control subjects We found stnkmgly similar frequencies for each
genotype (Table 3) This suggests that patients and control subjects
ongmated from the same source population, and further supports the
absence of an association between factor VII levels and venous throm-
bosis
Our results show that plasma fibrmogen, a determmant of artenal
thrombosis is also a nsk factor for venous thrombosis, while the factor
VII plasma concentration is unrelated to deep vem thrombosis, which is
supported by the data from the DNA analysis of polymorphisms
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